Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · January 30, 2024

Adjuvant Abemaciclib Plus Endocrine Therapy for HR-Positive, HER2-Negative, High-Risk Early Breast Cancer

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes
J. Clin. Oncol 2024 Jan 09;[EPub Ahead of Print], P Rastogi, J O'Shaughnessy, M Martin, F Boyle, J Cortes, HS Rugo, MP Goetz, EP Hamilton, CS Huang, E Senkus, A Tryakin, I Cicin, L Testa, P Neven, J Huober, Z Shao, R Wei, V André, M Munoz, B San Antonio, A Shahir, N Harbeck, S Johnston

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading